Prostate Specific Antigen News Archive

Many Men Lack Information on PSA Screening Pros, Cons

Many Men Lack Information on PSA Screening Pros, Cons

In 2014, 33.9% of men reported that their health care providers failed to communicate the benefits and risks of PSA-based screening, an increase from 2012.

PSA, PSAD Less Predictive of Aggressive PCa in Black Men

PSA, PSAD Less Predictive of Aggressive PCa in Black Men

Study finds that PSA and PSAD indicated prostate cancer above Gleason score 6 for white men only.

5-Year PCa-Specific Mortality Declined With Increased PSA Testing

5-Year PCa-Specific Mortality Declined With Increased PSA Testing

From 1995 to 2011, prostate cancer deaths fell by 13.0% among Danish patients diagnosed with low-risk disease.

Black Patients May Be Adversely Affected by Less PSA Screening

Black Patients May Be Adversely Affected by Less PSA Screening

Black patients who met age criteria for PSA screening were 28% more likely to die of their prostate cancer than patients ineligible for screening.

Fewer Prostate Biopsies After USPSTF Limited PSA Screening

Fewer Prostate Biopsies After USPSTF Limited PSA Screening

Following the 2012 USPSTF recommendation against PSA screening in populations, rates of radical prostatectomy and biopsy have become significantly less common.

New Prostate Cancer Screening Algorithm Proposed

New Prostate Cancer Screening Algorithm Proposed

A PSA level of 1.5 ng/mL or higher should prompt primary care physicians to refer patients to a urologist for further evaluation.

Radiographic Progression of mCRPC Without Rising PSA

Radiographic Progression of mCRPC Without Rising PSA

In a PREVAIL trial post hoc analysis, nearly one fourth of men on enzalutamide had radiographic progression despite non-rising PSA.

PCa Deaths Rare Among Men With Benign 1st Biopsy and Low PSA

PCa Deaths Rare Among Men With Benign 1st Biopsy and Low PSA

After 20 years, the prostate cancer mortality rate was 0.7% for men with a PSA level of 10 ng/mL or less and benign initial biopsy results.

Digital Rectal Examination, PSA Testing Rates Declining

Digital Rectal Examination, PSA Testing Rates Declining

Decreases in use of screening following USPSTF recommendations against routine PSA screening.

PSA of 0.4 ng/mL Predicts PCa Progression

PSA of ≥0.4 ng/mL Predicts PCa Progression

Shows the strongest correlation between biochemical recurrence and subsequent systemic progression.

Midlife PSA Levels Predict Lethal Prostate Cancer

Midlife PSA Levels Predict Lethal Prostate Cancer

The odds of developing lethal prostate cancer were increased by 6.9 to 12.6 times for men aged 40 to 59 years with higher PSA values.

High PSA Predicts Elevated Risk of Lower Urinary Tract Symptoms

High PSA Predicts Elevated Risk of Lower Urinary Tract Symptoms

LUTS is 49% more likely to develop in men with a PSA level above 6 ng/mL versus 4 ng/mL or less.

Landmark PSA Screening Trial Results Challenged

Landmark PSA Screening Trial Results Challenged

The PLCO trial's conclusion that routine PSA testing does not affect prostate cancer mortality risk could be wrong.

PSA Screening More Likely Among Blacks

PSA Screening More Likely Among Blacks

The odds of PSA screening were higher among blacks than non-Hispanic whites.

Fluoroquinolones May Be Unwarranted for High PSA

Fluoroquinolones May Be Unwarranted for High PSA

PSA level declined by an average of 0.68 ng/mL in the treatment group.

Clinician Training Influences PSA Screening in Senior Veterans

Clinician Training Influences PSA Screening in Senior Veterans

Older men whose clinician was a physician trainee had substantially lower prostate-specific antigen (PSA) screening rates.

Prostate Biopsy Rates Fall Following Guideline Updates

Prostate Biopsy Rates Fall Following Guideline Updates

The proportion of biopsied men who have complications from the procedure rose from 14% to 18% from 2005 to 2014.

Only Conservative PSA Testing is Cost-Effective

Only Conservative PSA Testing is Cost-Effective

This includes less frequent screening and more restrictive biopsy referral criteria.

Impact of USPSTF Rec Against PSA Screening Varied for Urologists, PCPs

Impact of USPSTF Rec Against PSA Screening Varied for Urologists, PCPs

Differential effect of 2012 USPSTF recommendations for primary care providers, urologists.

Many Seniors Have Non-Recommended PSA Screening

Many Seniors Have Non-Recommended PSA Screening

Rate of unnecessary screening was 15.7% in men 65 years and older.

Lower PSA Thresholds Predict Increased PCa Risk in Veterans

Lower PSA Thresholds Predict Increased PCa Risk in Veterans

Prostate cancer is 1.4 times more likely to develop in those with a PSA level of 2.5 ng/mL or higher.

Black Men Produce Less PSA

Black Men Produce Less PSA

Equal serum prostate-specific antigen and prostate-specific antigen mass despite larger prostates.

Early PSA Response to Abiraterone Predicts Better Outcomes

Early PSA Response to Abiraterone Predicts Better Outcomes

A 50% or greater PSA decline at 15 days after start of treatment was associated with increased progression-free and overall survival.

Diagnostic Features May Help Men Avoid Prostate Biopsy

Diagnostic Features May Help Men Avoid Prostate Biopsy

Prostate-specific antigen density, total tumor length are significant predictors.

Impact of Less PSA Screening Following USPSTF Recs

Impact of Less PSA Screening Following USPSTF Recs

After, men undergoing prostate needle biopsy more likely to be diagnosed with high-risk disease.

PSA Screening May Harm ESRD Patients Awaiting Transplant

PSA Screening May Harm ESRD Patients Awaiting Transplant

Screening not linked to improved patient survival after transplant; may delay time to listing, transplant.

Post-Brachytherapy PSA Bounce Linked to Intercourse Satisfaction

Post-Brachytherapy PSA Bounce Linked to Intercourse Satisfaction

Researchers say they believe study findings support a hypothesis than ejaculation resulting from sexual intercourse might cause PSA bounce.

Repeating PSA Test Reduces Risk of Prostate Biopsy, PCa Diagnosis

Repeating PSA Test Reduces Risk of Prostate Biopsy, PCa Diagnosis

Men with a normal PSA upon repeat testing had a 78% lower risk of prostate cancer diagnosis than men with a second abnormal PSA result.

Prostate Cancer Active Surveillance Quality Questioned

Prostate Cancer Active Surveillance Quality Questioned

Only 4.5% of Medicare patients on active surveillance or watchful waiting for prostate cancer are monitored as closely as they should be.

Prostate Cancer ADT Strategies Offer Similar Efficacy, QoL

Prostate Cancer ADT Strategies Offer Similar Efficacy, QoL

The time to PSA progression in men with relapsing or locally advanced PCa was similar with intermittent and continuous androgen deprivation.

Exercise Training May Delay PCa Progression

Exercise Training May Delay PCa Progression

PSA doubling time increased from 28 to 76 months in patients performing exercise training.

Prostate Cancer Screening, Detection Both Down in US

Prostate Cancer Screening, Detection Both Down in US

But whether that's good or bad isn't yet clear

Ovarian Cancer Drug Promising for Prostate Tumors

Ovarian Cancer Drug Promising for Prostate Tumors

In small study, olaparib targeted gene mutation in men who had failed other therapy.

PCa Diagnoses Fall in Wake of USPSTF Screening Recommendation

PCa Diagnoses Fall in Wake of USPSTF Screening Recommendation

A year after the federal task force came out against routine PSA screening, diagnoses of low-risk PCa decreased by 38% and continued to fall.

Black Men with Low-Risk Prostate Cancer Produce Less PSA

Black Men with Low-Risk Prostate Cancer Produce Less PSA

Findings could have implications for active surveillance criteria for African Americans.

Mushroom Powder May Help PCa Patients With Biochemical Recurrence

Mushroom Powder May Help PCa Patients With Biochemical Recurrence

Reduction in prostate-specific antigen level in some patients with biochemical recurrence.

PCa Deaths Rare Among Low-Risk Patients on Active Surveillance

PCa Deaths Rare Among Low-Risk Patients on Active Surveillance

Men receiving active surveillance were 24 times more likely to die from causes other than prostate cancer over 15 years.

Early Chemotherapy Offers No Survival Edge in mCRPC

Early Chemotherapy Offers No Survival Edge in mCRPC

Giving docetaxel before abiraterone does not improve progression-free and overall survival compared with the reverse sequence.

MRI-TRUS Biopsy Aids Detection of Locally Recurrent PCa

MRI-TRUS Biopsy Aids Detection of Locally Recurrent PCa

The technique, with cognitive assistance, identified recurrent tumors in 80% of patients.

Prostate Health Index Predicts Post-RARP Prostate Cancer Recurrence

Prostate Health Index Predicts Post-RARP Prostate Cancer Recurrence

A PHI of 82 discriminated between patients with and without biochemical recurrence.

PCPs Screening Less with PSA Per USPSTF Recs

PCPs Screening Less with PSA Per USPSTF Recs

Primary care screening patterns have changed as a result of the USPSTF recommendation.

DRE Has Limited Value for Prostate Cancer Screening

DRE Has Limited Value for Prostate Cancer Screening

Biopsies triggered by an abnormal DRE alone were significantly less likely to detect clinically significant prostate cancer than biopsies triggered by an abnormal PSA alone.

Under and Over Imaging in Castration-Resistant Prostate Cancer

Under and Over Imaging in Castration-Resistant Prostate Cancer

Patients with higher PSA, shorter PSA doubling time more likely to have second bone scan.

PSA Rising While on Abiraterone? Taking It with Food May Help

PSA Rising While on Abiraterone? Taking It with Food May Help

In a small study of mCRPC patients, the median time on therapy increased by nearly 100 days and PSA declined in some subjects.

New Guideline for PCa Survivor Care Endorsed by ASCO

New Guideline for PCa Survivor Care Endorsed by ASCO

Guideline outlines recommended follow-up care for prostate cancer survivors

Underdiagnosis Common Among PCa Active Surveillance Candidates

Underdiagnosis Common Among PCa Active Surveillance Candidates

Just over 41% of patients eligible for active surveillance by European standards were found to have undergraded prostate cancer.

PSA Doubling Time Predicts Salvage Radiation Outcomes

PSA Doubling Time Predicts Salvage Radiation Outcomes

PSA doubling time of 6 months or less and seminal vesicle invasion were significant predictors of biochemical recurrence.

Urology Referrals for Elevated PSA Unchanged

Urology Referrals for Elevated PSA Unchanged

New study examined the effect of a U.S. Preventive Services Task Force 2012 recommendation against routine PSA screening.

Optimal PSA Threshold For Targeted Biopsy Identified

Optimal PSA Threshold For Targeted Biopsy Identified

Diagnostic usefulness of magnetic resonance imaging/ultrasound (MRI/US) fusion targeted prostate biopsy optimized in PSA level of 5.2 ng/mL or higher.

Rising PSA with Testosterone Gel Linked with Specific Factors

Rising PSA with Testosterone Gel Linked with Specific Factors

Greater PSA increases seen in older men and those with lower baseline testosterone.

Early Prostate Cancer Post-Operation PSA Values Useful

Early Prostate Cancer Post-Operation PSA Values Useful

PSA levels at day 30 found to predict biochemical relapse risk in men with positive surgical margins.

Good Prostate Cancer (PCa) Outcomes Possible Despite Salvage Radiation Failure

Good Prostate Cancer (PCa) Outcomes Possible Despite Salvage Radiation Failure

Men who had PSA relapse after receiving post-radical surgery salvage radiation therapy had a median overall survival of nearly 14 years.

Palpable Tumors Plus Low PSA May Up Prostate Cancer Death Risk

Palpable Tumors Plus Low PSA May Up Prostate Cancer Death Risk

New study highlights the importance of digital rectal examinations in PCa patients with normal-range PSA at diagnosis.

Lower PSA Predicts Favorable Salvage Radiotherapy Outcomes

Lower PSA Predicts Favorable Salvage Radiotherapy Outcomes

Reduced likelihood of biochemical recurrence of prostate cancer also linked to concomitant hormonal therapy and positive surgical margins.

New Findings May Explain PSA Bounce

New Findings May Explain PSA Bounce

Transient rises in PSA after radiotherapy may be due to late damage to healthy prostatic tissue, evidence suggests.

ADT May Be Safely Deferred After PSA Relapse

ADT May Be Safely Deferred After PSA Relapse

Immediate ADT found to offer little or no survival advantage to prostate cancer who experience biochemical recurrence.

Maximal Tumor Diameter Predicts PSA Failure Risk

Maximal Tumor Diameter Predicts PSA Failure Risk

This parameter can identify prostate cancer patients for whom adjuvant radiation therapy after radical prostatectomy may be of no benefit.

Post-Brachytherapy PSA Bounce Linked to Sexual Activity

Post-Brachytherapy PSA Bounce Linked to Sexual Activity

PSA bounce was associated with significantly higher scores on the International Index of Erectile Function-15 questionnaire.

Study: Low-Risk PCa Increasingly T1c

Study: Low-Risk PCa Increasingly T1c

Men diagnosed with low-risk prostate cancer today have lower PSA levels and tumor volume than men 15 years ago.

PSA Nadir in ADT Recipients: The Lower, The Better

PSA Nadir in ADT Recipients: The Lower, The Better

The nadir should be below 0.01 ng/mL because even levels of 0.01 to 0.2 ng/mL predict an increased risk of adverse outcomes.

CTCs Predict Survival in Men with Metastatic CRPC

CTCs Predict Survival in Men with Metastatic CRPC

Higher circulating tumor cell counts are associated with an increased risk of death.

PSA Screening Declining, Especially Among Urologists

PSA Screening Declining, Especially Among Urologists

Trend follows the 2012 release of a U.S. Preventive Services Task Force recommendation against such testing.

Bisphenol A May Boost Prostate Cancer Risk

Bisphenol A May Boost Prostate Cancer Risk

Elevated urinary levels of the organic compound were found in men with prostate cancer than in those without it.

PSA Levels, Kinetics May Predict PCa Bone Scan Results

PSA Levels, Kinetics May Predict PCa Bone Scan Results

High PSA and short PSA double time are associated with a greater likelihood of a positive bone scan.

Added Criteria May Identify Prostate Cancer Surveillance Candidates

Added Criteria May Identify Prostate Cancer Surveillance Candidates

Additional predictors guide selection of patients for active surveillance programs.

Model Predicts PCa Overdiagnosis Risk

Model Predicts PCa Overdiagnosis Risk

New nomogram could help clinicians and patients make treatment decisions.

Transperineal Prostate Biopsy Trumps TRUS

Transperineal Prostate Biopsy Trumps TRUS

TPTPB should be regarded as the gold-standard test in men with two sets of negative TRUS-guided biopsies and rising PSA levels, researchers say.

Primary-Care Physicians Drive PSA Testing for Older Men

Texas study shows that PSA screening was ordered for 41% of men aged 75 and older, largely because of decisions by primary-care physicians.

Prostate Cancer Screening Cost Nearly Half Billion in 2009

Prostate Cancer Screening Cost Nearly Half Billion in 2009

Biopsy-related procedures accounted for much of the cost.

PSADT May Give Wrong Prostate Cancer Prognosis

Relying on PSA doubling time from just one year of active surveillance can result in as many as one in five prostate cancer patients being advised to undergo curative treatment that may be unnecessary.

Short-Term PSA Testing to Calculate PSADT is Error-Prone

One year of PSA test results can lead to 10%-20% of men being misclassified as having a high risk of prostate cancer progression.

PCa Decision Aids Do Not Sway Men

Print- and Web-based tools presenting the benefits and limitations of PSA testing served to help men resolve their own conflicts.

Elevated PSA Linked to Shiftwork

Findings support the notion of a link with sleep or circadian disruption.

Low-Grade PCa Patients Benefit from Surveillance

Low-Grade PCa Patients Benefit from Surveillance

Post-PSA intro, big drop in advanced-stage cancers but only modest drop in high Gleason score cancers.

PSA Levels May Predict Hypogonadism

PSA levels below 0.65 ng/mL provide the best sensitivity and specificity (65.2% and 55.5%, respectively) for predicting severe hypogonadism.

Men Still Undergo PSA Testing Despite USPSTF Guidelines

Men Still Undergo PSA Testing Despite USPSTF Guidelines

Findings based on survey even after informing men about the USPSTF recommendation.

Denosumab Delays Bone Mets in Non-Metastatic CRPC

The drug prolonged development of bone metastasis by a median of 7.2 months.

Enzalutamide Safe, Effective for Hormone-Naïve Prostate Cancer

PSA declined by a median of 99.6% and bone mineral density remained stable from baseline to week 25.

Saw Palmetto Has No Effect on PSA

Saw palmetto remains the most common herbal treatment for men with LUTS.

Updated Prostate Cancer Screening Guidelines Announced

Shared decision-making about screening recommended for men aged 55-69 years.

Prostate Cancer Deaths Occurring at Older Ages

Median survival time from diagnosis improved by a median of 43 months from the pre-PSA to the post-PSA era.

Prostate Cancer AS May Be OK Despite Higher PSA

Pathologic progression not more likely in patients who start active surveillance with a PSA of 10 ng/mL or higher, study finds.

Prostate Cancer Severity Not Linked to Obesity

Study reveals no significant association between BMI and prebiopsy PSA, Gleason score, clinical T stage, and D'Amico risk.

For Older Men, Prostate Biopsy Uncommon After Abnormal PSA

For Older Men, Prostate Biopsy Uncommon After Abnormal PSA

Most men with biopsy-detected cancer undergo treatment, regardless of age, comorbidities.

PSA in Midlife Can Predict Later Risk of Prostate Cancer Mets

PSA in Midlife Can Predict Later Risk of Prostate Cancer Mets

PSA at age 40 to 55 correlates with risk of death or metastasis during 25 to 30 years of follow-up.

Lower PSA Predicts Better Survival in Sipuleucel T Recipients

New findings provide a rationale for immunotherapy as an early step in sequencing treatment algorithm for mCRPC.

Men Need to Be Informed of PSA Testing Benefits, Harms, ACP Says

Men Need to Be Informed of PSA Testing Benefits, Harms, ACP Says

American College of Physicians' new screening guidance committee urges caution

Prostate Cancer Deaths Can Occur Despite Normal Initial PSA

New findings raise questions about PSA screening criteria.

Prostate Cancer Benefit Lasts Up to Nine Years After Last Screening

Stopping PSA testing at age 70 may be premature, at least in men with high-risk disease and long life expectancies, researchers conclude.

PSA Screening Lowers Prostate Cancer Death Risk

The survival benefit is limited to men aged 55-69 years at initial screening, large European study finds.

Alternative PSA Screening Strategies Could Reduce Harm

Alternative PSA Screening Strategies Could Reduce Harm

Use of biennial strategy with longer interval for low PSA levels reduces tests, false-positive results

Docs' Use of Informed Decision-Making for PSA Testing Varies

Docs' Use of Informed Decision-Making for PSA Testing Varies

Much of variation in use of informed decision-making due to physicians' attitudes to screening.

PSA Levels Higher in Sedentary Men, Study Finds

PSA concentrations are higher in men who engage in more sedentary behavior and lower levels of light physical activity, a study found.

Low Neutrophil Count May Predict Prostate Cancer

Researchers urge prostate biopsies for men with a low neutrophil count and increased serum PSA level.

Intermittent and Continuous ADT Offer Similar Survival

The estimated seven-year cumulative rates of prostate cancer-related death were 18% and 15%, respectively, for intermittent and continuous androgen suppression.

PSA Change After 5-Alpha Reductase Therapy Aids Cancer Diagnosis

PSA Change After 5-Alpha Reductase Therapy Aids Cancer Diagnosis

Findings in men with persistently increased serum PSA and previously negative prostate biopsies

Benefits of Prostate-Specific Antigen Testing Remain Unclear

Benefits of Prostate-Specific Antigen Testing Remain Unclear

Provisional clinical opinion from ASCO suggests benefit for men with longer life expectancy.

Pomegranate Extract Found to Increase PSA Doubling Time

Phase 2 trial shows benefit in men with recurrent prostate cancer.

Cure Possible Despite Positive Lymph Nodes

Long-term PSA relapse-free survival after radical prostatectomy (RP) and pelvic lymph node dissection (PLND) is possible in a subset of patients with low volume nodal metastases, a researcher reported at the American Urological Association 2012 annual meeting.

PSA Screening Lowers Prostate Cancer Mortality

PSA-based screening significantly decreases the risk of dying from prostate cancer (PCa), according to updated results of a large European study.

Sign Up for Free e-newsletters